WINT Windtree Therapeutics Future Price to Earnings

Windtree Therapeutics (WINT) is developing a closed-loop peptide system for the treatment of cardiogenic shock. The company's forward P/E ratio displayed on GURU.Markets visualizes this process, where the parameter value equals 0.00. Robotic blood biochemistry analysis optimizes clinical tests, while management, operating under strict resource austerity, focuses on identifying strategic partners for business development.

WINT - Windtree Therapeutics, Inc. Price to Future Earnings Ratio over the range 07/04/2022 - 09/06/2025

Financial and market metric breakdowns for Windtree (WINT)

- stock quotes and analyst forecast:

Stock Price Windtree Therapeutics|WINT - Analyst Median Target

- market capitalization data:

Market Value Windtree Therapeutics Inc.|WINT - Business Value

- balance sheet equity data:

Book Value per Share Windtree Therapeutics|WINT - Accounting Capitalization|Market Cap to Net Assets Ratio windtreetx.com|WINT - Aggregate Business Assets

- business debt structure and liquidity details:

- earnings and market ratios statistics:

WINT - Profit After Payment of Taxes|Projected Future Earnings Windtree Therapeutics|WINT - Company Value to Net Income|Forward P/E Multiple Windtree Therapeutics|WINT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Windtree Therapeutics Inc.|WINT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Windtree Therapeutics|WINT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months windtreetx.com|WINT - Earnings per share trend in current year|Earnings growth forecast for next year Windtree Therapeutics

Analysis of all company metrics:Windtree Therapeutics, Inc.

Windtree Therapeutics (WINT) resilience to volatility is driven by exclusive patents in cardiogenic shock therapy and stringent FDA oversight, rendering future revenues dependent on regulatory milestones. Analyzing the company's expected P/E ratio at 0.00, an investor assesses the current share price through the lens of projected earnings to determine the asset's degree of overheating and the risk of a prolonged capital freeze.

Competitors of Windtree Therapeutics (WINT)

Forward P/E Multiple REGN|Market Cap to Projected Earnings iRhythm Technologies, Inc.|Future Price to Earnings Lantheus Medical Imaging LNTH|MLYS: Price to Future Earnings Ratio|HeartFlow, Inc. - Forward P/E Multiple|KMTS (kestramedical.com) - Price to Future Earnings Ratio|ESPR (Esperion) - Projected Price to Earnings|AMRN: Market Cap to Future Earnings Ratio|Future Price to Earnings Anteris|TNYA: Future Price to Earnings Multiple|Forward P/E Multiple CVRX|MIST - Projected Price to Earnings Ratio|Forward P/E Multiple CRDL (Cardiol Therapeutics Inc.)|HeartBeam Inc (BEAT) - Projected Price to Earnings Ratio|TENX: Projected Price to Earnings|Future Price to Earnings Multiple ADGM (Adagio Medical, Inc.)|BCDA (BioCardia, Inc.) - Projected Price to Earnings|VTAK: Market Cap to Future Earnings Ratio|ABIO (ARCA Biopharma Inc) - Forward P/E Multiple|ACST: Future Price to Earnings Multiple|Forward P/E Multiple AVTE|VERV - Projected Price to Earnings Ratio